Why Scalable Purification Is Essential for Commercial Biologic Drug Manufacturing — BCI

The transition from a laboratory-scale breakthrough to a commercially viable therapeutic is perhaps the most treacherous phase in the life cycle of a biologic drug. In the world of modern medicine, where monoclonal antibodies, recombinant proteins, and gene therapies are becoming the standard of care for chronic diseases, the ability to manufacture these complex molecules at scale is paramount. However, a significant bottleneck persists in the “downstream” phase of production. While upstream titers — the amount of product generated by cell cultures — have increased exponentially over the last decade, the technologies used to purify these drugs have struggled to keep pace. Visit us : https://biochromatographix.com/

• 42